Plasma-derived medicinal products: Demand and clinical use

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Grazzini, Giuliano ^a   Mannucci, Pier Mannuccio ^b   Oleari, Fabrizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; HETASTARCH; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; PLASMA DERIVED MEDICINAL PRODUCT; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD TRANSFUSION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; GOVERNMENT; HUMAN; ITALY; PATIENT SAFETY; PHARMACY; PLASMA; PRESCRIPTION; QUALITY CONTROL; REVIEW; TREATMENT INDICATION;

HUMANS; PHARMACEUTICAL PREPARATIONS; PLASMA;

EID: 84885640572     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.002s     Document Type: Review

References (38)

1. th, 2001. Commission Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2001:311:0067:0128:en:PDF. Accessed on 30/08/2013.
2. Caraceni P, Tufoni M, Bonavita ME. Clinical use of human albumin. Blood Transfus 2013; 11 (Suppl 4): s18-25.
3. Quinti I, Pesce AM, Bonanni L, et al. Clinical use of polyvalent immunoglobulins. Blood Transfus 2013; 11 (Suppl 4): s33-9.
4. Morfini M, Coppola A, Franchini M, Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Transfus 2013; 11 (Suppl 4): s55-63.
5. th list (April 2013). World Health Organisation. Available at: http://www.who.int/medicines/ publications/essentialmedicines/18th-EML-Final-web-8Jul13.pdf. Accessed on 30/08/2013.
6. th list (April 2013). World Health Organisation. Available at: http://www.who.int/ medicines/publications/essentialmedicines/4th-EMLc-FINAL-web-8Jul13.pdf. Accessed on 30/08/2013.
7. th, 2005. Legge 21 ottobre 2005, n. 219 "Nuova disciplina delle attività trasfusionali e della produzione nazionale degli emoderivati. Available at: http://www.centronazionalesangue.it/content/legge-21-ottobre-2005-2-219. Accessed on 30/08/2013.
8. Calizzani G, Profili S, Candura F, et al. Plasma and plasmaderived medicinal product self-sufficiency: the Italian case. Blood Transfus 2013; 11 (Suppl 4): s118-31.
9. Calizzani G, Lanzoni M, Candura F, et al. Analisi della domanda dei principali medicinali plasmaderivati in Italia. Anni 2007-2011. Roma: Istituto Superiore di Sanità 2012. Rapporti ISTISAN 12/53. http://www. centronazionalesangue.it/sites/default/files/rapporto-istisan-12-53.pdf. Accessed on 30/08/2013.
10. th, 2003. Commission Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 "setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components amending Directive 2001/83/EC". Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030:0040: EN:PDF. Accessed on 30/08/2013.
11. th, 2004. Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:091:0025:0039: EN:PDF. Accessed on 30/08/2013.
12. st, 2005. Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L:2005:256:0032:0040:EN:PDF. Accessed on 30/08/2013.
13. st, 2005. Commission Directive 2005/62/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Community standards and specifications relating to a quality system for blood establishments of the European Parliament and of the Council. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:256:0041:0048: EN:PDF. Accessed on 30/08/2013.
14. th, 2011. Decreto del Ministero della Salute 20 gennaio 2011: "Programma di autosufficienza nazionale del sangue e dei suoi prodotti per l'anno 2010". Available at: http://www.centronazionalesangue.it/sites/default/files/dm-20.01. 2011-programma-nazionale-autosufficienza-2010.pdf. Accessed on 28/02/2013 30/08/2013.
15. st, 2011. Decreto del Ministero della Salute 7 ottobre 2011: "Programma di autosufficienza nazionale del sangue e dei suoi prodotti, per l'anno 2011". Available at: http://www.centronazionalesangue.it/sites/default/files/d.m.-7. 10.11-programma-nazionale-autosufficienza-2011-gu-22.11.11. pdf. Accessed on 30/08/2013.
16. th, 2012. Decreto del Ministro della Salute del 4 settembre 2012. Programma di autosufficienza nazionale del sangue e dei suoi prodotti per l'anno 2012. Available at: http://www.centronazionalesangue.it/sites/default/files/ programmazione-autosuff-2012-0.pdf. Accessed on 30/08/2013.
17. rd, 2008. Decreto legislativo 20 dicembre 2007, n. 261. Revisione del decreto legislativo 19 agosto 2005, n. 191, recante attuazione della direttiva 2002/98/CE che stabilisce norme di qualità e di sicurezza per la raccolta, il controllo, la lavorazione, la conservazione e la distribuzione del sangue umano e dei suoi componenti. Available at: http://www. centronazionalesangue.it/sites/default/files/DECLEG20DIC2007.pdf. Accessed on 30/08/2013.
18. WHO Expert Group. Expert Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary non-remunerated blood donation (VNRBD). Vox Sang 2012; 103: 337-42.
19. Vaglio S, Calizzani G, Lanzoni M, et al. The demand for human albumin in Italy. Blood Transfus 2013; 11 (Suppl 4): s26-32.
20. Quinti I, Coluzzi S, Pulvirenti F, et al. Polyvalent immunoglobulins: challenges and perspectives. Blood Transfus 2013; 11 (Suppl 4): s40-4.
21. Candura F, Lanzoni M, Calizzani G, et al. The demand for polyvalent immunoglobulins in Italy. Blood Transfus 2013; 11 (Suppl 4): s45-54.
22. Calizzani G, Profili S, Candura F, et al. The demand for factor VIII and for factor IX in Italy and the toll fractionation product surplus management. Blood Transfus 2013; 11 (Suppl 4): s64-76.
23. Arcieri R, Molinari AC, Farace S. Present and future challenges in the treatment of haemophilia: the patient's perspective. Blood Transfus 2013; 11 (Suppl 4): 82-5.
24. Liumbruno GM, Franchini M, Lanzoni M, et al. Clinical use and the Italian demand for antithrombin. Blood Transfus 2013; 11 (Suppl 4): s86-93.
25. Franchini M, Liumbruno GM, Lanzoni M, et al. Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus 2013; 11 (Suppl 4): s94-100.
26. Coppola A, Tagliaferri AR, Calizzani G, et al. Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. Blood Transfus 2013; 11 (Suppl 4): s101-9.
27. Calizzani G, Vaglio S, Candura F, et al. The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy. Blood Transfus 2013; 11 (Suppl 4): s6-12.
28. De Angelis V, Breda A. Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? Blood Transfus 2013; 11 (Suppl 4): s132-7.
29. Lanzoni M, Biffoli C, Candura F, et al. Plasma-derived medicinal products in Italy: information sources and flows. Blood Transfus 2013; 11 (Suppl 4): s13-7.
30. Lanzoni M, Candura F, Calizzani G, et al. Public expenditure for plasma-derived and recombinant medicinal products in Italy. Blood Transfus 2013; 11 (Suppl 4): s110-7.
31. Grazzini G, Ceccarelli A, Calteri D, et al Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing. Blood Transfus 2013; 11 (Suppl 4): s138-47.
32. Grazzini G. Clinical appropriateness of blood component transfusion: regulatory requirements and standards set by the Scientific Society in Italy. Blood Transfus 2008; 6: 186-90.
33. Robert P. The Marketing Research Bureau (MRB). The Worldwide Plasma Fractions Market 2008. April 2010 Ed. Orange, CT: The Marketing Research Bureau, Inc.; 2010
34. Wise J. Europe recommends ban on common plasma substitute. BMJ 2013; 17; 346: f3942.
35. st century through competitive tendering. Haemophilia 2013; DOI 10.1111/hae.12169. healthpol.2013.05.022.
36. Calizzani G, Vaglio S, Arcieri R, et al. Models for institutional and professional accreditation of haemophilia centres in Italy. Haemophilia 2013; 19: e248-55.
37. European guidelines for the certification of Haemophilia Centres, 7 June 2013. European HAemophilia NETwork (EUHANET). Available at: http://www.euhanet. org/docs/Euhanet-European-guidelines-for-the-certification-of-Haemophilia- Centres-2013.pdf. Accessed on 30/08/2013.
38. th, 2013. Accordo 13 marzo 2013. Accordo, ai sensi dell'articolo 4 del decreto legislativo 28 agosto 1997, n. 281, tra il Governo, le Regioni e le Province autonome di Trento e Bolzano sulla definizione dei percorsi regionali o interregionali di assistenza per le persone affette da Malattie Emorragiche Congenite (MEC). Available at http://fedemo.it/wp-content/uploads/2013/03/GU-n.-107-09.05.2013- Assistenza-MEC. pdf. Accessed on 30/08/2013.